 |
|
Chronic Recurrent Lymphocytic Sweet Syndrome as a Predictive Marker of Myelodysplasia
A Report of 9 Cases
Marie-Dominique Vignon-Pennamen, MD;
Caroline Juillard, MD;
Michel Rybojad, MD;
Daniel Wallach, MD;
Marie-Thérèse Daniel, MD;
Patrice Morel, MD;
Olivier Verola, MD;
Anne Janin, MD, PhD
Arch Dermatol. 2006;142:1170-1176.
ABSTRACT
| |
Background Sweet syndrome is an acute neutrophilic dermatosis that occurs with malignant diseases, mainly myeloid hemopathies, in about 20% of cases. When associated with myelodysplasia, Sweet syndrome may be clinically atypical. It can be histologically unusual. Concomitant infiltration of mature neutrophils and immature myeloid cells has been reported, and its significance is still debated. In few patients, lymphocytic infiltrates are the presenting feature of Sweet syndrome with myelodysplasia.
Observations We present 9 male adult patients with chronic Sweet syndrome, all with recurrent eruptions of erythematous and annular plaques that were associated with relapsing polychondritis in 4 of the 9 patients. Results from sequential biopsies showed that infiltrates were initially composed of lymphocytes and that neutrophilic dermal infiltration typical of Sweet syndrome occurred 24 to 96 months later, except in 2 cases. Moreover, atypical mononuclear cells were present on all initial biopsy specimens and strongly reacted to CD68 and myeloperoxidase, indicating a myeloid origin. Myelodysplastic syndrome occurred in all 9 patients, concomitantly with the neutrophilic infiltrate in 4 cases.
Conclusions Lymphocytic infiltrates with a clinical aspect of Sweet syndrome might represent the initial stage of a cutaneous dysgranulopoiesis syndrome and should lead to the research of atypical myeloid cells in skin infiltrate, blood, and bone marrow for the early detection of an associated myelodysplastic syndrome.
INTRODUCTION
Sweet syndrome is a disorder characterized by tender erythematous plaques predominating on the face, neck, and upper limbs. Appearing mainly in women at mid-life, it is typically accompanied by fever and systemic symptoms including arthralgia, myalgia, and ocular involvement. Common laboratory abnormalities include leukocytosis and an elevated erythrocyte sedimentation rate.1-3 Histologically, an intense neutrophilic infiltrate of the mid and papillary dermis is associated with dermal edema. There may be leukocytoclasia but no evidence of vasculitis.3-4 Although the etiology is unknown, Sweet syndrome has been associated with a variety of autoimmune disorders and malignancies.5 About 20% of cases occur with malignant diseases, mainly myeloid hemopathies.6
The myelodysplastic syndromes constitute a broad spectrum of hematologic disorders in which the primary defect lies in the multipotent hematopoietic stem cell. Myelodysplastic syndromes are characterized by atypia of both the bone marrow and peripheral blood cells and pancytopenia, and they mainly affect older patients. They are classified in subgroups based on morphologic criteria, percentage of bone marrow myeloblasts, and cytogenetic and karyotypic abnormalities.7 Transformation into acute myelogenous leukemia occurs in 6% to 37% of patients with myelodysplastic syndrome.8 Sweet syndrome is commonly associated with myelodysplastic syndrome.9-10 In these cases, necrotic aspects and the presence of immature myeloid cells are reported.11-12 Recently, 2 cases of Sweet syndrome associated with myelodysplasia have been reported, with lymphocytic infiltrates as the initial feature.13 Therefore, we revised the sequential clinical and histological data of 9 patients with Sweet syndrome associated with myelodysplasia.
REPORT OF CASES
Over a period of 10 years (1995-2005), 70 patients with cutaneous disease and myelodysplastic syndrome were followed up in Hôpital Saint-Louis, Paris, France. Nine of these patients had chronic Sweet syndrome. For these 9 patients, at the different times of follow-up, the distribution and occurrence of skin lesions, laboratory abnormalities, hematologic diagnosis, and treatment were reviewed (Table 1). Hematologic diagnoses were established on peripheral blood smears and bone marrow aspiration and then were subclassified according to the French-American-British (FAB) classification scheme.7 For each patient, 3 to 7 skin biopsies had been performed. On these sequential biopsies, the analysis focused on the distribution of the infiltrates and their density. Cytological composition of the infiltrates was assessed, and their respective density in neutrophils, eosinophils, lymphocytes, macrophages, and atypical mononuclear cells was graded.
|
|
|
|
Table 1. Clinical Findings and Course
|
|
|
For immunohistochemical studies, representative sections were examined by the streptavidin-biotin peroxidase method, using appropriate positive and negative controls. Slides were processed on the automated immunostainer Nexes (Ventana, Tucson, Ariz). The antibodies used, their specificity, their source, and dilution are given in Table 2.
|
|
|
|
Table 2. Antibodies Used in This Study
|
|
|
CLINICAL FINDINGS
The 9 patients were men aged 55 to 72 years (median age, 64.5 years). The clinical features were similar in all patients (Table 1). Clinical aspects of the recurrences were also similar over the course of their disease (Figure 1A and C), with multiple flares of edematous erythematous plaques over the face, trunk, and arms. On the trunk, plaques had an annular configuration with sharply marked borders. Some of them extended and became confluent. On the limbs, plaques and purple nodules were observed in 8 cases, with pustules on plaques in cases 3, 4, and 7. Three patients had purpuric papules with vasculitis (cases 1-3). All 9 patients had fever, with arthralgia in cases 3, 4, 8, and 9 or episcleritis in case 8. Findings from laboratory tests showed an elevated erythrocyte sedimentation rate (all patients), leukopenia (cases 2 and 6), and anemia (case 1). The diagnosis of Sweet syndrome was initially proposed on clinical grounds. After analysis of the first results of the skin biopsies, subacute lupus erythematosus and Jessner lymphocytic infiltration were also discussed. In all 9 cases, the lesions resolved spontaneously and recurred. The course of the disease was characterized by multiple relapses with progressively reduced normal intervals. Auricular and nasal chondritis appeared in 4 patients (cases 1, 3, 5, and 8) about 3 years after the onset of skin disease. The diagnosis of relapsing polychondritis was made on clinical grounds and confirmed by cartilage biopsy findings showing necrosis of chondrocytes and vasculitis. There were no systemic manifestations of relapsing polychondritis in our patients.
|
|
|
|
Figure 1. Clinical and histological aspects in "initial" lymphocytic Sweet syndrome (case 2: A and C) and in "late" neutrophilic Sweet syndrome (case 1: B and D). A, Disseminated erythematous plaques over the trunk and arms. B, Erythematous plaques with annular configuration. C, Dense lymphocytic infiltrates located in the superficial and middermis (hematoxylin-eosin, original magnification x10). D, Massive dermal neutrophilic infiltrates without vasculitis (hematoxylin-eosin, original magnification x20).
|
|
|
Though bone marrow aspiration was initially normal in 2 patients (cases 1 and 6), all patients developed leukopenia and/or anemia and macrocytosis when dermatosis relapsed. A myelodysplastic syndrome was finally diagnosed in all patients, 2 to 7 years after the onset of their skin symptoms (median, 3.5 years). The subtypes were refractory anemia (cases 2-5), refractory anemia with blasts excess (case 1), and unclassified myelodysplasia (cases 6-9).
Follow-up ranged from 3 to 10 years (median, 5.4 years). High-dose oral prednisone (60-80 mg/d) provided complete remission in all patients. However, the lesions worsened on tapering dosages, and 25 mg/d was necessary to control the disease. No significant benefit was obtained with hydroxychloroquine sulfate (200 mg twice a day), dapsone (100 mg/d), and colchicine (2 mg/d). Six patients were treated with thalidomide (100 mg/d for about 3 months), leading to complete resolution of cutaneous disease in 4 patients. On discontinuation of the medication for mental confusion, deep venous thrombosis, or thrombotic microangiopathy, skin lesions recurred in 3 other patients. In all 9 patients, the myelodysplastic syndrome was controlled by transfusions (3 patients) and erythropoietin therapy (1 patient). There was no progression to acute myeloid leukemia (median follow-up of 30 months). One patient was lost to follow-up, and 1 patient is alive and receiving oral prednisone (20 mg/d). The 7 other patients died from sepsis or vascular complications 3 to 48 months (median, 26.5 months) after myelodysplasia was diagnosed. The duration of cutaneous disease before patients died ranged from 3 to 9 years (median, 5.5 years).
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL FINDINGS
Forty sequential skin biopsy specimens were reviewed. For each patient, 3 to 7 biopsies were performed from 3 to 54 months. Two histological patterns, lymphocytic and neutrophilic, were observed. A review of the patients' files showed that in 7 cases, the lymphocytic pattern preceded the neutrophilic pattern. These 2 patterns are accordingly named "initial" and "late" Sweet syndrome in our patients (Figure 1B and D). In the initial stage, 20 biopsy specimens from 7 patients (cases 1, 2, 4-6, 8, and 9) showed mononuclear infiltrates consistent with Jessner lymphocytic infiltrate, lupus erythematosus, or drug-related eruption. The infiltrates were moderate to dense, located in the superficial and deep dermis (Figure 2A and B). Superficial edema was observed in most of the cases and epidermis was spared. The infiltrates were composed predominantly of lymphocytes, histiocytes, and atypical mononuclear cells with large, eccentric, elongated, twisted, or kidney-shaped basophilic or vesicular nuclei and eosinophilic cytoplasm. These cells were located around blood vessels or dispersed in edema. Findings from immunohistochemical studies showed that atypical mononuclear cells were CD68 and myeloperoxidase positive (Figure 2C and D) and CD34 negative. CD56 was expressed by a few cells in 1 patient. The lymphocytes were mainly CD3 positive.
|
|
|
|
Figure 2. Histological features of "initial" Sweet syndrome (case 8). A, Perivascular mononuclear infiltrate; B, cells with a histiocytic appearance had kidney-shaped, twisted vesicular nuclei; C, strong immunoexpression for CD68; and D, immunoreactivity for myeloperoxidase (hematoxylin-eosin, original magnification x40 [A], x100 [B], x20 [C], and x20 [D]).
|
|
|
In 2 patients (cases 3 and 7), initial biopsy specimens diagnosed as dermal lymphocytic infiltration were not available for review. These patients were referred to one of us for evaluation of lupus erythematosus that did not respond to conventional therapy.
In the late stage, 16 sequential biopsy specimens from 7 patients (cases 1-4, 6, 7, and 9) were examined 2 to 8 years after the onset of disease and showed neutrophilic infiltrates consistent with the diagnosis of Sweet syndrome. The infiltrates were dense to massive, predominantly or exclusively composed of polymorphonuclear neutrophils in 3 cases (cases 3, 7, and 9) and associated with lymphocytes or histiocytes in the other cases. Superficial edema was observed, but there was no vasculitis. In 5 patients (cases 1, 4, 6, 7, and 9), medium-sized mononuclear atypical cells with eccentric, kidney-shaped nuclei, similar to cells observed in initial biopsy specimens, were also found (Figure 3), with the same immunohistochemical characteristics. In 2 patients (cases 5 and 8), no biopsies were performed in subsequent recurrences, and typical neutrophilic infiltrates were not observed.
|
|
|
|
Figure 3. Histological features of "late" Sweet syndrome (case 9). A, Neutrophilic infiltrates; B, immature granulocytes mixed with mature neutrophils (hematoxylin-eosin, original magnification x40 [A] and x100 [B]).
|
|
|
Vasculitis was observed in 3 patients (cases 1-3), with relapsing polychondritis in 2 of them. In 5 patients (cases 1, 2, 4, 6, and 9), "initial" lymphocytic and "late" neutrophilic patterns were observed. In these patients, the composition of the infiltrates and their respective density in lymphocytes, neutrophils, and atypical mononuclear cells were compared at the onset of skin disease and the onset of myelodysplasia (Figure 4), revealing that neutrophils were the predominating cells at the time of diagnosis of myelodysplasia.
|
|
|
|
Figure 4. Density of infiltrate is presented for each cell type as 4 categories according to the proportion of cells (A, lymphocytes; B, neutrophils; and C, atypical mononuclear cells) in the skin biopsy specimens (0, absence or negligible amount of cells; +, <10%; ++, 10%-50%; and +++, 50%-100%). Categories are represented on the vertical scale by the median value for each category, except for "+," which was placed at 10%. For each patient, T1 was the first biopsy performed at the onset of the skin disease; T2 was the biopsy performed at the time of diagnosis of myelodysplasia.
|
|
|
COMMENT
Sweet syndrome was described in 1964 by Robert Douglas Sweet2 as an "acute febrile neutrophilic dermatosis" with the following characteristics: pyrexia; neutrophilia; erythematous painful cutaneous plaques located on the upper extremities, head, and neck; a dense dermal infiltrate of neutrophils; and a prompt response to corticosteroid therapy. All 9 patients we studied had criteria proposed for the diagnosis of Sweet syndrome.14 They had both major criteria (clinical aspect of lesions and sequentially acquired neutrophilic infiltrate) and 3 minor criteria (fever, associated disease, and response to corticosteroid therapy). Sweet syndrome associated with myelodysplasia tended to be atypical. There is no sex predilection. Cutaneous lesions are more frequently vesicular, bullous, or even necrotic and ulcerative.11 It may lack systemic features such as neutrophilia or fever. Our series confirms most of the atypical features reported in Sweet syndrome associated with myelodysplasia. All of our cases were men. They had recurrent flares of a florid eruption with fever. Tender plaques with a dusky red center and well-defined, sharply demarcated borders were localized on the trunk. When cutaneous lesions appeared, some patients had leukopenia or anemia with macrocytosis. However, findings from bone marrow aspiration initially performed in 2 patients were normal. Four patients had relapsing polychondritis 1 to 4 years after the onset of cutaneous lesions at the time of diagnosis of myelodysplasia in 2 patients. Although unexplained, the association of relapsing polychondritis and myelodysplasia is considered significant.15 The only efficient treatment was corticosteroid therapy (prednisone), at 25 mg/d or more. Four patients had improvement with thalidomide therapy. Unfortunately, severe adverse effects were observed, and treatment was discontinued. The most important point was established by studying the results of sequential biopsies. In all 9 patients, the infiltrates were initially lymphocytic, and neutrophils were observed only after a mean of 4 years of evolution (range, 24-96 months). Lymphocytic infiltrates in the initial biopsy specimens were predominantly composed of T lymphocytes along with a CD68-positive monocytic population. In initial biopsy specimens, monocytic cells with kidney shape or vesicular nuclei and eosinophilic cytoplasm were observed, and the most striking finding was their strong reactivity for myeloperoxidase, a finding suggesting that these cells were immature myeloid cells, possibly precursors of neutrophils. In findings from sequential biopsies, 7 patients had neutrophilic infiltrates mixed with the same atypical mononuclear cells.
Sweet syndrome is associated with myelodysplastic syndromes or hematological malignancies in about 20% of cases.6 Sweet syndrome occurs at onset or follows a myelodysplasia9 and may herald a transformation into acute myeloid leukemia.16 The recurrence of Sweet syndrome may coincide with or precede a hematological relapse.6 No transformation into acute myeloid leukemia occurred in our cases. However, 7 of the 9 patients died in a follow-up period of 3 to 9 years, confirming the poor prognosis of Sweet syndrome associated with myelodysplasia.17
Interestingly, cutaneous lesions clinically characteristic of Sweet syndrome, but with lymphocytic infiltrate and atypical mononuclear myeloperoxidase-positive cells, preceded myelodysplasia in all 9 cases.
Four other cases (4 men aged 56 to 79 years) of atypical Sweet syndrome associated with myelodysplasia have been reported.13, 18-19 Myelodysplastic syndrome occurred at the onset of cutaneous disease in 2 patients or followed it 3 years later in 1. Skin disease was clinically diagnosed as Sweet syndrome but was initially composed of lymphocytic infiltrates. With the recurrence of cutaneous lesions, dermal neutrophilic infiltrates were later found in 3 patients. In 2 cases, immunohistochemical staining of mononuclear infiltrates showed a mixed population of CD68+, CD4+, and CD8+ cells. No more characterization of cells was reported.
In a series of 37 patients with Sweet syndrome who had undergone sequential biopsies, the initial lymphocytic stage was followed by neutrophilic and then histiocytic infiltrates.20 Our findings confirm this view. However, an initial stage of lymphocytic infiltration preceding, for many years, neutrophilic infiltrates had never been recorded. Furthermore, in our patients, lymphocytes were accompanied with monocytic cells that strongly reacted to CD68 and myeloperoxidase.
Abundant histiocytes have already been reported in 2 series of 18 and 12 cases of Sweet syndrome.21-22 Unfortunately, myeloperoxidase expression was not studied.
In a recent series of 41 patients with Sweet syndrome, an immunoreactivity for CD15, CD45, CD68, and lysozyme was consistent with a monocytic-histiocytic profile.23 Moreover, intense myeloperoxidase reactivity was detected in the histiocytic cells. The authors ruled out the possibility of acute or chronic myelogenous leukemia. All patients were treated with oral prednisone or nonsteroidal anti-inflammatory drugs. The cutaneous lesions resolved within a few days and did not recur. The authors concluded that some acute lesions of Sweet syndrome included immature myeloid cells and proposed to name these forms "histiocytoid Sweet syndrome." This variant of Sweet syndrome, concerning patients with an acute, nonrelapsing disease, without predominantly lymphocytic infiltrates and without myeloid hemopathy, appears to be different from our cases.
In our 9 cases, the concomitant presence of immature myeloid cells and mature polymorphonuclear neutrophils within the same lesion has already been reported.12, 24-25 The significance of this population of immature neutrophilic granulocytes in the skin is still discussed.26 They can constitute the incipient presence of a specific leukemic infiltrate and can represent the well-differentiated type of leukemia cutis. When cutaneous lesions are the initial presentation, an overt leukemia appeared a few months later in most patients.27 The circulating immature myeloid cells may also be innocent bystanders recruited to the skin through an inflammatory reaction stimulated by the Sweet syndrome. The ability of immature myeloid cell precursors to migrate to the skin in myelogenous leukemia is well known.28 Because blast cells recruited in the skin have the ability to differentiate to a morphologically and phenotypically heterogenous population including mature granulocytes, it can be suggested that immature myeloid cells admixed with neutrophils constitute a specific infiltrate.29 The atypical cells of leukemia cutis might also develop into mature neutrophils of Sweet syndrome through therapy-induced differentiation either with G-CSF25 or with all-trans retinoic acid.24 Finally, neutrophils infiltrating the skin could also be clonally derived.25
These hypotheses do not clarify the mechanism of the lesions we observed. Timing between the onset of cutaneous disease and myelodysplasia is not compatible with recruitment into the skin of leukemic cells not detected in blood or bone marrow. Our patients never received granulocyte colony-stimulating factor. Moreover, we found immature granulocytes with lymphocytic infiltrates in the initial biopsy specimens. We cannot rule out recruitment by dermal lymphocytes cytokines in our cases. The role of T lymphocytes in regulating neutrophilic skin inflammation is well known.30 CXCL8-producing T cells facilitate skin inflammation. These lymphocytes can promote the attraction of immature granulocytes by the secretion of cytokines such as interleukin 8, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor  , which can prolong cell survival, differentiation, and maturation to neutrophils.
In conclusion, in this series of 9 adult men, recurrent Sweet syndrome was initially characterized by lymphocytic infiltrates and atypical mononuclear cells identified as immature granulocytes. It later evolved to neutrophilic infiltrates and was associated with myelodysplasia. All those features may represent the cutaneous component of the dysgranulopoiesis syndrome. Why cutaneous disease appeared 2 to 8 years before myelodysplastic syndrome was identified remains unexplained, but this fact is of practical clinical importance and may help in the early diagnosis of myelodysplasia and management of patients.
AUTHOR INFORMATION
Correspondence: Marie-Dominique Vignon-Pennamen, MD, Hôpital Saint-Louis, 1 ave Claude Vellefaux, 75475 Paris CEDEX 10, France (dominique.vignon-pennamen{at}wanadoo.fr).
Accepted for Publication: March 1, 2006.
Author Contributions: Study concept and design: Vignon-Pennamen, Wallach, Verola, and Janin. Acquisition of data: Vignon-Pennamen, Juillard, Rybojad, and Morel. Analysis and interpretation of data: Vignon-Pennamen, Juillard, Rybojad, Wallach, Daniel, Morel, Verola, and Janin. Drafting of the manuscript: Vignon-Pennamen, Wallach, Morel, and Janin. Critical revision of the manuscript for important intellectual content: Juillard, Rybojad, Wallach, Daniel, Morel, Verola, and Janin. Administrative, technical, and material support: Vignon-Pennamen, Juillard, Rybojad, and Verola.
Financial Disclosure: None reported.
Author Affiliations: Departments of Dermatology (Drs Vignon-Pennamen, Juillard, Rybojad, and Morel), Biological Hematology (Dr Daniel), and Pathology and U728 INSERM (Institut National de la Santé et de la Recherche Médicale), University Paris VII, University Institute of Hematology, Institut Français de Recherche 105 (Drs Vignon-Pennamen, Verola, and Janin), Hôpital Saint-Louis; and Department of Dermatology, Hôpital Tarnier-Cochin (Dr Wallach); Assistance Publique–Hôpitaux de Paris, Paris, France.
REFERENCES
| |
1. Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol. 2003;42:761-778.
FULL TEXT
|
ISI
| PUBMED
2. Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964;76:349-356.
ISI
| PUBMED
3. Callen JP. Neutrophilic dermatoses. Dermatol Clin. 2002;20:409-419.
FULL TEXT
|
ISI
| PUBMED
4. Malone JC, Slone SP, Wills-Frank LA, et al. Vascular inflammation (vasculitis) in Sweet syndrome: a clinicopathologic study of 28 biopsy specimens from 21 patients. Arch Dermatol. 2002;138:345-349.
FREE FULL TEXT
5. Fett DL, Gibson LE, Su WP. Sweet's syndrome: systemic signs and symptoms and associated disorders. Mayo Clin Proc. 1995;70:234-240.
ISI
| PUBMED
6. Cohen PR, Talpaz M, Kurzrock R. Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol. 1988;6:1887-1897.
ABSTRACT
7. Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol. 2005;32:S3-S10.
ISI
| PUBMED
8. Sanz GF, Sanz MA, Vallespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395-408.
FREE FULL TEXT
9. Avivi I, Rosenbaum H, Levy Y, Rowe J. Myelodysplastic syndrome and associated skin lesions: a review of the literature. Leuk Res. 1999;23:323-330.
FULL TEXT
|
ISI
| PUBMED
10. Reuss-Borst MA, Pawelec G, Saal JG, Horny HP, Muller CA, Waller HD. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol. 1993;84:356-358.
ISI
| PUBMED
11. Suzuki Y, Kuroda K, Kojima T, Fujita M, Iseki T, Shinkai H. Unusual cutaneous manifestations of myelodysplastic syndrome. Br J Dermatol. 1995;133:483-486.
FULL TEXT
|
ISI
| PUBMED
12. Tomasini C, Aloi F, Osella-Abate S, Dapavo P, Pippione M. Immature myeloid precursors in chronic neutrophilic dermatosis associated with myelodysplastic syndrome. Am J Dermatopathol. 2000;22:429-433.
ISI
| PUBMED
13. Evans AV, Sabroe RA, Liddell K, Russell-Jones R. Lymphocytic infiltrates as a presenting feature of Sweet's syndrome with myelodysplasia and response to cyclophosphamide. Br J Dermatol. 2002;146:1087-1090.
FULL TEXT
|
ISI
| PUBMED
14. von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31:535-556.
ISI
| PUBMED
15. Diebold L, Rauh G, Jager K, Lohrs U. Bone marrow pathology in relapsing polychondritis: high frequency of myelodysplastic syndromes. Br J Haematol. 1995;89:820-830.
ISI
| PUBMED
16. Soppi E, Nousiainen T, Seppa A, Lahtinen R. Acute febrile neutrophilic dermatosis (Sweet's syndrome) in association with myelodysplastic syndromes: a report of three cases and a review of the literature. Br J Haematol. 1989;73:43-47.
ISI
| PUBMED
17. Aractingi S, Bachmeyer C, Dombret H, Vignon-Pennamen D, Degos L, Dubertret L. Simultaneous occurrence of two rare cutaneous markers of poor prognosis in myelodysplastic syndrome: erythema elevatum diutinum and specific lesions. Br J Dermatol. 1994;131:112-117.
FULL TEXT
|
ISI
| PUBMED
18. Browning CE, Dixon JE, Malone JC, Callen JP. Thalidomide in the treatment of recalcitrant Sweet's syndrome associated with myelodysplasia. J Am Acad Dermatol. 2005;53:S135-S138.
FULL TEXT
|
ISI
| PUBMED
19. Yamamoto T, Soejima K, Yokozeki H, Koyano T, Katayama I, Nishioka K. Unusual annular erythema associated with myelodysplastic syndrome. Dermatology. 2001;202:70-72.
FULL TEXT
|
ISI
| PUBMED
20. Jordaan HF. Acute febrile neutrophilic dermatosis: a histopathological study of 37 patients and a review of the literature. Am J Dermatopathol. 1989;11:99-111.
ISI
| PUBMED
21. Delabie J, De Wolf-Peeters C, Mooren M, Karien K, Roskams T, Desmet V. Histiocytes in Sweet's syndrome. Br J Dermatol. 1991;124:348-353.
FULL TEXT
|
ISI
| PUBMED
22. Bourke JF, Jones JL, Fletcher A, Graham-Brown RA. An immunohistochemical study of the dermal infiltrate and epidermal staining for interleukin 1 in 12 cases of Sweet's syndrome. Br J Dermatol. 1996;134:705-709.
FULL TEXT
|
ISI
| PUBMED
23. Requena L, Kutzner H, Palmedo G, et al. Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol. 2005;141:834-842.
FREE FULL TEXT
24. Piette WW, Trapp JF, O'Donnell MJ, Argenyi Z, Talbot EA, Burns CP. Acute neutrophilic dermatosis with myeloblastic infiltrate in a leukemia patient receiving all-trans-retinoic acid therapy. J Am Acad Dermatol. 1994;30:293-297.
ISI
| PUBMED
25. Magro CM, De Moraes E, Burns F. Sweet's syndrome in the setting of CD34-positive acute myelogenous leukemia treated with granulocyte colony stimulating factor: evidence for a clonal neutrophilic dermatosis. J Cutan Pathol. 2001;28:90-96.
FULL TEXT
|
ISI
| PUBMED
26. Vignon-Pennamen MD, Aractingi S. Sweet's syndrome and leukemia cutis: a common skin homing mechanism? Dermatology. 2003;206:81-84.
FULL TEXT
|
ISI
| PUBMED
27. Longacre TA, Smoller BR. Leukemia cutis: analysis of 50 biopsy-proven cases with an emphasis on occurrence in myelodysplastic syndromes. Am J Clin Pathol. 1993;100:276-284.
ISI
| PUBMED
28. Reuss-Borst MA, Klein G, Waller HD, Muller CA. Differential expression of adhesion molecules in acute leukemia. Leukemia. 1995;9:869-874.
ISI
| PUBMED
29. Kaiserling E, Horny HP, Geerts ML, Schmid U. Skin involvement in myelogenous leukemia: morphologic and immunophenotypic heterogeneity of skin infiltrates. Mod Pathol. 1994;7:771-779.
ISI
30. Schaerli P, Britschgi M, Keller M, et al. Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol. 2004;173:2151-2158.
FREE FULL TEXT
|
